Replimune (REPL) Total Current Liabilities (2018 - 2026)
Replimune (REPL) posted Total Current Liabilities of $58.2 million for Q1 2026, up 16.25% sequentially from $50.1 million in Q4 2025, and down 6.63% YoY from $62.4 million in Q1 2025.
Analysis
Replimune (REPL) Total Current Liabilities (2018 - 2026) Analysis & Trends
Replimune has reported Total Current Liabilities for 9 years, with the latest figure at $58.2 million in Q1 2026.
- Quarterly Total Current Liabilities fell 6.63% year-over-year to $58.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.2 million (down 6.63% YoY) and the FY2026 annual result came in at $58.2 million, down 6.63% from the prior year.
- Total Current Liabilities improved to $58.2 million in Q1 2026 per REPL's latest filing, from $50.1 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $62.4 million in Q1 2025 and troughed at $20.3 million in Q2 2022.
- A 5-year average of $40.4 million and a median of $39.8 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2026: Total Current Liabilities surged 69.23% in 2023, then slipped 6.63% in 2026.
- Over 5 years, Total Current Liabilities stood at $26.5 million in 2022, then soared by 46.05% to $38.6 million in 2023, then climbed by 23.91% to $47.9 million in 2024, then increased by 4.59% to $50.1 million in 2025, then rose by 16.25% to $58.2 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $58.2 million, $50.1 million, and $52.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | 38.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 38.41 Mn |
| Mar 31, 2026 | 58.23 Mn |
| Dec 31, 2025 | 50.09 Mn |
| Sep 30, 2025 | 52.90 Mn |
| Jun 30, 2025 | 59.56 Mn |
| Mar 31, 2025 | 62.36 Mn |
| Dec 31, 2024 | 47.89 Mn |
| Sep 30, 2024 | 43.79 Mn |
| Jun 30, 2024 | 35.68 Mn |
| Mar 31, 2024 | 40.44 Mn |
| Dec 31, 2023 | 38.65 Mn |
| Sep 30, 2023 | 39.83 Mn |
| Jun 30, 2023 | 32.24 Mn |
| Mar 31, 2023 | 33.83 Mn |
| Dec 31, 2022 | 26.46 Mn |
| Sep 30, 2022 | 23.54 Mn |
| Jun 30, 2022 | 20.31 Mn |
| Mar 31, 2022 | 20.76 Mn |
| Dec 31, 2021 | 18.29 Mn |
| Sep 30, 2021 | 16.64 Mn |